🌸 #IBDUpdates Jan 2025 🌸
Antibiotic Exposure and Risk of New-Onset Inflammatory Bowel Disease: A Systematic Review and Dose-Response Meta-Analysis - Clinical Gastroenterology and Hepatology 

🌸Introdction
Antibiotic Usage: Antibiotic prescriptions have significantly increased, with a 65% rise in 76 countries from 2000 to 2015.
Gut Microbiota and Health: Growing recognition of the gut microbiota's role in health has raised concerns that antibiotics may disrupt microbial ecology, potentially leading to diseases.
Association with Diseases: Antibiotic exposure has been linked to an increased risk of metabolic and immune diseases, including inflammatory bowel disease (IBD).
Initial Meta-analysis (2014): The first meta-analysis on antibiotic exposure and IBD risk, conducted by Ungaro et al., included small observational studies.
Emerging Evidence: New epidemiological studies, including large-scale national case-control and cohort studies, have further explored the connection, but the relationship remains controversial, particularly for ulcerative colitis (UC).
🌸Study Findings
Antibiotic exposure was significantly linked to an increased risk of new-onset IBD, affecting both Crohn's disease (CD) and ulcerative colitis (UC), as well as in children and adults.
Antibiotic Classes: Most antibiotic classes were associated with a higher IBD risk, with metronidazole and quinolones showing relatively higher risk estimates.
Dose-Response Relationship: A positive nonlinear dose-response relationship was found between the number of antibiotic prescriptions and IBD risk.
🌸Implications for IBD Management
If antibiotic exposure is confirmed as an environmental trigger for IBD, it could significantly impact IBD management and prevention.
Strengthening antibiotic stewardship by adhering to prescription guidelines is crucial, not only for general health but also in the prevention of IBD.